Developer docs
API playgroundTry for free, no card

Search company profiles

Tissue Testing Technologies

Full company profile

uuid002azl5

Namestring
Tissue Testing Technologies
Legal namestring
Tissue Testing Technologies LLC
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Tissue Testing Technologies LLC (also operating under the name "T3") was a private biotechnology company founded in 2014 and based in North Charleston, United States. The company specialized in biopreservation technology focused on extending the viability of organs, tissues, and cells outside the body for use in transplantation and therapeutic applications. Its core technology addressed a fundamental constraint in transplant medicine — the short preservation window for biological materials — and was positioned to serve healthcare providers, specifically transplant centers, with use cases spanning organ preservation for transplants, tissue storage, and cell storage for therapeutic applications.

No specific named products, pricing models, distribution channels, management team members, funding rounds, patents, certifications, or AI capabilities were disclosed in available sources. The company's public website remained in a "Coming Soon" placeholder state, indicating either limited commercial deployment or an early-stage commercial profile prior to the acquisition. The company's overall visibility in public data sources is low, consistent with a small private biotech operating in a specialized niche.

On December 15, 2025, Tissue Testing Technologies was acquired by LifeNet Health, a strategic operating company in the regenerative medicine sector. The acquisition transferred T3's biopreservation capabilities into LifeNet Health's broader portfolio, with stated rationale of improving organ and tissue preservation and extending therapeutic opportunities. Following the acquisition, Tissue Testing Technologies ceased to operate as an independent entity and is now a subsidiary under LifeNet Health's ownership.

Short descriptiontext

Tissue Testing Technologies LLC (T3) was a private North Charleston biotech firm developing biopreservation technology to extend organ, tissue, and cell viability for transplantation centers and therapeutic applications. It was acquired by LifeNet Health on December 15, 2025.

Operating statusenum
Acquired
Ownership categoryenum
akta.pro rankint
HeadquartersNorth Charleston, United States
HQ citystring
North Charleston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biopreservation technology, tissue preservation solutions, organ preservation, regenerative medicine, transplant tissue storage
Industry1 code
PRIMARYHLAAABAK
Cell Therapy Quality, Analytics & Release Testing (potency, sterility, comparability)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Testing Laboratories and Services541380
  • Medical and Diagnostic Laboratories62151
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
  • Biological Products, (No Disgnostic Substances)2836
Product category
Tissue Biopreservation
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Tissue Testing Technologies LLC (T3) is a biotechnology firm that develops biopreservation technology focused on organ and tissue preservation. The company provides preservation solutions for research purposes, with use cases spanning organ preservation for transplants, tissue storage, and cell storage for therapeutic applications. The company was acquired by LifeNet Health on December 15, 2025.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Tissue Testing Technologies LLC (T3) was a biotech company specializing in biopreservation technology. The company was acquired by LifeNet Health on December 15, 2025. No specific named products, modules, or service offerings were identified in the available source data.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

MTF Biologics is a major tissue bank and regenerative-medicine organization distributing allograft tissues — broad incumbent serving overlapping end markets (transplant and therapeutic use of preserved biological materials).

TypeBroad incumbent
Description

LifeNet Health is T3's acquirer and the largest nonprofit organ-procurement and tissue-banking organization in the U.S. — broad incumbent that now owns T3's biopreservation capabilities and serves the same transplant-center customer base.

TypeDirect peer
Description

Organ Recovery Systems (now part of global transplant solutions) provides Lifeport kidney perfusion machines and preservation fluids — direct peer in perfusion-based organ preservation technology and transplant-center delivery.

TypeEmerging player
Description

Vitanova Biomedical works on tissue and organ preservation technologies targeting improved viability for transplant and regenerative medicine — adjacent niche player with partial overlap to T3's biopreservation focus.

TypeDirect peer
Description

XIVIO develops machine perfusion and preservation solutions for kidneys, livers, and lungs — comparable biopreservation technology serving the same transplant-center workflows as T3.

6TransMedics
TypeDirect peer
Description

TransMedics offers the Organ Care System for heart, lung, and liver preservation, competing head-to-head in extending ex-vivo organ viability for transplantation — same customer segment and use case as T3.

TypeDirect peer
Description

BioLife Solutions provides biopreservation media, storage, and shipping products (CryoStor, HypoThermosol) for cells and tissues — directly comparable preservation technology with overlap in cell/tissue therapy storage.

TypeDirect peer
Description

Bridge to Life supplies preservation solutions and perfusion devices for organ and tissue transplantation — directly overlapping with T3's preservation/transport offering for transplant centers.

TypeDirect peer
Description

OrganOx develops normothermic machine perfusion platforms (e.g., metra) for liver and kidney preservation — directly comparable to T3's biopreservation/organ-viability mission and the same transplant-center customer base.

TypeDirect peer
Description

Paragonix provides hypothermic organ preservation and transport devices (SherpaPak, LungGuard) — a direct competitor to T3 in extending organ viability windows and serving transplant centers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tissue Testing Technologies

Tissue Biopreservationtissuetestingtech.com

Tissue Testing Technologies LLC (T3) was a private North Charleston biotech firm developing biopreservation technology to extend organ, tissue, and cell viability for transplantation centers and therapeutic applications. It was acquired by LifeNet Health on December 15, 2025.

What Tissue Testing Technologies does

Tissue Testing Technologies LLC (also operating under the name "T3") was a private biotechnology company founded in 2014 and based in North Charleston, United States. The company specialized in biopreservation technology focused on extending the viability of organs, tissues, and cells outside the body for use in transplantation and therapeutic applications. Its core technology addressed a fundamental constraint in transplant medicine — the short preservation window for biological materials — and was positioned to serve healthcare providers, specifically transplant centers, with use cases spanning organ preservation for transplants, tissue storage, and cell storage for therapeutic applications.

No specific named products, pricing models, distribution channels, management team members, funding rounds, patents, certifications, or AI capabilities were disclosed in available sources. The company's public website remained in a "Coming Soon" placeholder state, indicating either limited commercial deployment or an early-stage commercial profile prior to the acquisition. The company's overall visibility in public data sources is low, consistent with a small private biotech operating in a specialized niche.

On December 15, 2025, Tissue Testing Technologies was acquired by LifeNet Health, a strategic operating company in the regenerative medicine sector. The acquisition transferred T3's biopreservation capabilities into LifeNet Health's broader portfolio, with stated rationale of improving organ and tissue preservation and extending therapeutic opportunities. Following the acquisition, Tissue Testing Technologies ceased to operate as an independent entity and is now a subsidiary under LifeNet Health's ownership.

Tissue Testing Technologies firmographics

Firmographics
Name
Tissue Testing Technologies
Legal name
Tissue Testing Technologies LLC
Website
https://tissuetestingtech.com
Company type
Private
Founded year
2014
Operating status
Acquired
Short description
Tissue Testing Technologies LLC (T3) was a private North Charleston biotech firm developing biopreservation technology to extend organ, tissue, and cell viability for transplantation centers and therapeutic applications. It was acquired by LifeNet Health on December 15, 2025.
Ownership category
akta.pro rank

Tissue Testing Technologies industry classification

Industry
Product category
Tissue Biopreservation
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Testing Laboratories and Services (541380), Medical and Diagnostic Laboratories (62151)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAK
Cell Therapy Quality, Analytics & Release Testing (potency, sterility, comparability)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Biopreservation technology
  • Tissue preservation solutions
  • Organ preservation
  • Regenerative medicine
  • Transplant tissue storage

Where Tissue Testing Technologies is headquartered

Location

Headquarters

HQ city
North Charleston
HQ country
United States
HQ region
North America

Markets served

Tissue Testing Technologies business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Tissue Testing Technologies product offering

Product offering

Core offering

Tissue Testing Technologies LLC (T3) is a biotechnology firm that develops biopreservation technology focused on organ and tissue preservation. The company provides preservation solutions for research purposes, with use cases spanning organ preservation for transplants, tissue storage, and cell storage for therapeutic applications. The company was acquired by LifeNet Health on December 15, 2025.

Product overview

Tissue Testing Technologies LLC (T3) was a biotech company specializing in biopreservation technology. The company was acquired by LifeNet Health on December 15, 2025. No specific named products, modules, or service offerings were identified in the available source data.

Differentiator

Problem solved

Functional benefit

Companies that use Tissue Testing Technologies

Customer profile

Segments1 record

Ideal customer profiles1 record

Tissue Testing Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Tissue Testing Technologies partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves1 record

Expansion highlights2 records

Tissue Testing Technologies competitors and assessment

Company assessment

Broad incumbents

  • MTF Biologics: MTF Biologics is a major tissue bank and regenerative-medicine organization distributing allograft tissues — broad incumbent serving overlapping end markets (transplant and therapeutic use of preserved biological materials).
  • LifeNet Health: LifeNet Health is T3's acquirer and the largest nonprofit organ-procurement and tissue-banking organization in the U.S. — broad incumbent that now owns T3's biopreservation capabilities and serves the same transplant-center customer base.

Direct peers

  • Organ Recovery Systems: Organ Recovery Systems (now part of global transplant solutions) provides Lifeport kidney perfusion machines and preservation fluids — direct peer in perfusion-based organ preservation technology and transplant-center delivery.
  • XIVIO Perfusion: XIVIO develops machine perfusion and preservation solutions for kidneys, livers, and lungs — comparable biopreservation technology serving the same transplant-center workflows as T3.
  • TransMedics: TransMedics offers the Organ Care System for heart, lung, and liver preservation, competing head-to-head in extending ex-vivo organ viability for transplantation — same customer segment and use case as T3.
  • BioLife Solutions: BioLife Solutions provides biopreservation media, storage, and shipping products (CryoStor, HypoThermosol) for cells and tissues — directly comparable preservation technology with overlap in cell/tissue therapy storage.
  • Bridge to Life: Bridge to Life supplies preservation solutions and perfusion devices for organ and tissue transplantation — directly overlapping with T3's preservation/transport offering for transplant centers.
  • OrganOx: OrganOx develops normothermic machine perfusion platforms (e.g., metra) for liver and kidney preservation — directly comparable to T3's biopreservation/organ-viability mission and the same transplant-center customer base.
  • Paragonix Technologies: Paragonix provides hypothermic organ preservation and transport devices (SherpaPak, LungGuard) — a direct competitor to T3 in extending organ viability windows and serving transplant centers.

Emerging players

  • Vitanova Biomedical: Vitanova Biomedical works on tissue and organ preservation technologies targeting improved viability for transplant and regenerative medicine — adjacent niche player with partial overlap to T3's biopreservation focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks4 records

Key highlights4 records

Customer concentration

Tissue Testing Technologies social profiles

Digital presence

Tissue Testing Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tissue Testing Technologies leadership team

Management profile

Number of profiles

Tissue Testing Technologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tissue Testing Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tissue Testing Technologies

What does Tissue Testing Technologies do?

Tissue Testing Technologies LLC (T3) is a biotechnology firm that develops biopreservation technology focused on organ and tissue preservation. The company provides preservation solutions for research purposes, with use cases spanning organ preservation for transplants, tissue storage, and cell storage for therapeutic applications. The company was acquired by LifeNet Health on December 15, 2025.

When was Tissue Testing Technologies founded?

Tissue Testing Technologies was founded in 2014.

Where is Tissue Testing Technologies based?

Tissue Testing Technologies is headquartered in North Charleston, United States, in the North America region.

Who are Tissue Testing Technologies's main competitors?

Broad incumbents on record are MTF Biologics and LifeNet Health. Direct peers are Organ Recovery Systems, XIVIO Perfusion, TransMedics, BioLife Solutions, Bridge to Life, OrganOx and Paragonix Technologies. Vitanova Biomedical is listed as an emerging player.

Does Tissue Testing Technologies have an API?

No public API is recorded for Tissue Testing Technologies.

What industry is Tissue Testing Technologies in?

Tissue Testing Technologies's product category is Tissue Biopreservation. Its primary akta.pro industry code is HLAAABAK, Cell Therapy Quality, Analytics & Release Testing (potency, sterility, comparability). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCryovials Market worth $0.31 billion by 2031 - Exclusive Report by MarketsandMarkets™MarketsandMarkets projects the cryovials market to grow from $0.24 billion in 2026 to $0.31 billion by 2031, a 5.5% CAGR. Glass cryovials and cell and gene therapy applications are expected to see the highest growth rates, driven by biobanking and advanced therapies.LifenethealthLifeNet Health Advances Regenerative Medicine with the Acquisition of Biopreservation Leader, Tissue Testing TechnologiesLifeNet Health has acquired Tissue Testing Technologies LLC (T3), a biotechnology company specializing in biopreservation technologies for clinical and research applications. T3's vitrification preservation and controlled warming technologies address critical limitations in organ and cell storage that currently limit transplant availability and therapeutic development. The acquisition combines T3's proprietary biopreservation platforms with LifeNet Health's existing regenerative medicine capabilities to extend organ viability and accelerate research pipelines for therapies relying on preserved tissues.PR NewswireLifeNet Health Advances Regenerative Medicine with the Acquisition of Biopreservation Leader, Tissue Testing TechnologiesLifeNet Health, a global leader in regenerative medicine headquartered in Virginia Beach, has acquired Tissue Testing Technologies LLC (T3), a Charleston-based biotechnology company specializing in biopreservation. T3's vitrification preservation and controlled warming technologies address critical limitations in organ and cell storage by extending viability during transport, potentially improving transplant success rates and expanding the types of tissues available for transplantation including cartilage, heart valves, and meniscus. The acquisition enables LifeNet Health to scale T3's preservation solutions globally, accelerate research pipelines for therapies relying on preserved tissues, and create end-to-end solutions for clinicians and researchers.YahooLifeNet Health Advances Regenerative Medicine with the Acquisition of Biopreservation Leader, Tissue Testing TechnologiesLifeNet Health, a global leader in regenerative medicine headquartered in Virginia Beach, has acquired Tissue Testing Technologies LLC (T3), a Charleston-based biotechnology company specializing in biopreservation. T3's proprietary vitrification preservation and controlled warming technologies address critical limitations in organ and tissue storage, enabling more organs to reach transplant recipients in optimal condition and expanding the types of tissues available for transplantation. The acquisition combines T3's foundational preservation technologies with LifeNet Health's existing platforms to create end-to-end solutions for clinicians and researchers, accelerating research pipelines for therapies that rely on preserved tissues.